Instil Bio, Inc.NASDAQ: TIL

Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

· Issued by Instil Bio, Inc. via GlobeNewswire

Summary by 6ix AI

Instil Bio, a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, reported a net loss of $4.2 million, or $0.62 a share, for the third quarter ended September 30, 2026, compared to $13.6 million, or $2.01 a share, as corrected, a year earlier.

Key details

  • Cash, cash equivalents, restricted cash, marketable securities and long-term investments were approximately $67.1 million as of September 30, 2026, compared to $76.3 million as of December 31, 2025; Instil expects this to fund its current operating plan through 2027.
  • Net loss for the nine months ended September 30, 2026 was $13.0 million, or $1.92 a share, compared to $63.5 million, or $9.58 a share, as corrected, for the same period of 2025.
  • Research and development expenses were $0.2 million for the third quarter of 2026, compared to $9.1 million a year earlier; general and administrative expenses were $5.8 million, compared to $6.3 million, as corrected.
  • Non-GAAP net loss per share (a measure not following US generally accepted accounting principles), which excludes non-cash stock-based compensation and restructuring and impairment charges, was $0.48 for the third quarter of 2026, compared to $1.75, as corrected, a year earlier.
  • Instil found errors in earlier financial statements relating to property taxes on its Tarzana, California facility and how amounts reimbursed by the facility's tenant were presented, plus other immaterial errors. It says they were not material, no prior filing is being amended, and 2025 figures are shown as corrected.

What’s still pending

  • Instil intends to internally develop or in-license programs to build a portfolio of development subsidiaries.
  • The expectation that cash will fund operations through 2027 is a company projection.

6ix AI wrote this summary from the release below and checked it against the release.

DALLAS, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.

Recent Highlights:

  • Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.
  • Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately $67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027.

Third Quarter 2026 Financial and Operating Results:

As of September 30, 2026, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $67.1 million, which consisted of $2.5 million in cash and cash equivalents, $0.4 million in restricted cash, $59.5 million in marketable securities and $4.6 million in long-term investments, compared to $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash and $69.5 million in marketable securities. Instil expects that its cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026 will enable it to fund its operating plan through 2027.

In-process research and development expenses were nil for the three and nine months ended September 30, 2026, compared to nil and $10.0 million for the three and nine months ended September 30, 2025, respectively.

Research and development expenses were $0.2 million and $1.2 million for the three and nine months ended September 30, 2026, respectively, compared to $9.1 million and $21.2 million for the three and nine months ended September 30, 2025, respectively.

General and administrative expenses were $5.8 million and $17.5 million for the three and nine months ended September 30, 2026, respectively, compared to $6.3 million and $22.7 million, as corrected, for the three and nine months ended September 30, 2025, respectively.

Restructuring and impairment charges, net were a reversal of costs of $0.1 million and a charge of $1.1 million for the three and nine months ended September 30, 2026, respectively, compared to nil and $16.6 million for the three and nine months ended September 30, 2025, respectively.

Net loss was $4.2 million and $13.0 million for the three and nine months ended September 30, 2026, respectively, compared to $13.6 million and $63.5 million, as corrected, for the three and nine months ended September 30, 2025, respectively. Net loss per share, basic and diluted, was $0.62 and $1.92 for the three and nine months ended September 30, 2026, respectively, compared to $2.01 and $9.58, as corrected, for the three and nine months ended September 30, 2025, respectively. Non-GAAP net loss per share, basic and diluted, was $0.48 and $1.32 for the three and nine months ended September 30, 2026, respectively, compared to $1.75 and $6.00, as corrected, for the three and nine months ended September 30, 2025, respectively; see the reconciliation of GAAP to non-GAAP measures below.

In preparing its third-quarter 2026 financial statements, Instil identified errors in previously issued financial statements relating to property taxes on its Tarzana, California facility and the presentation of amounts reimbursed by the facility’s tenant, as well as certain other immaterial errors. The errors were not material to any previously issued financial statements, and no prior filing is being amended. Instil has corrected the prior-period information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and the 2025 amounts in this release are presented as corrected.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

About Instil Bio

Instil Bio, Inc. is a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs. For more information, visit www.instilbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding establishing a portfolio of asset-focused development subsidiaries, internally developing or in-licensing programs, and building a diversified portfolio of development candidates; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other macroeconomic factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and Instil ’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.

Contacts:

Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com

Media Relations:

Kimberly Ha
KKH Advisors
1-917-291-5744
kimberly.ha@kkhadvisors.com

INSTIL BIO, INC.
SELECTED FINANCIAL DATA
Selected Condensed Consolidated Balance Sheet Data
(Unaudited; in thousands)
September 30, 2026December 31, 2025
Cash, cash equivalents, restricted cash, marketable securities and long-term investments$67,091$76,295
Total assets$195,645$204,515
Total liabilities$93,081$91,844
Total stockholders’ equity$102,564$112,671
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except share and per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Operating expenses:
In-process research and development$—$—$—$10,000
Research and development2339,1271,17221,241
General and administrative5,8336,34417,51022,689
Restructuring and impairment charges, net(81)—1,09216,622
Total operating expenses5,98515,47119,77470,552
Loss from operations(5,985)(15,471)(19,774)(70,552)
Interest income6158931,9253,112
Interest expense(1,554)(1,582)(4,688)(4,398)
Other rental income2,6972,6918,0908,076
Gain on contract termination——1,620—
Other (expense) income, net(4)(118)(196)267
Net loss$(4,231)$(13,587)$(13,023)$(63,495)
Net loss per share, basic and diluted$(0.62)$(2.01)$(1.92)$(9.58)
Weighted-average shares used in computing net loss per share, basic and diluted6,781,9766,757,7426,781,9766,629,949
INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share
(Unaudited; in thousands, except share and per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Net loss$(4,231)$(13,587)$(13,023)$(63,495)
Adjustments:
Non-cash stock-based compensation expense9841,7683,0057,087
Restructuring and impairment charges, net(81)—1,09216,622
Non-GAAP net loss$(3,328)$(11,819)$(8,926)$(39,786)
Net loss per share, basic and diluted$(0.62)$(2.01)$(1.92)$(9.58)
Adjustments:
Non-cash stock-based compensation expense per share0.150.260.441.07
Restructuring and impairment charges, net per share(0.01)—0.162.51
Non-GAAP net loss per share, basic and diluted*$(0.48)$(1.75)$(1.32)$(6.00)
Weighted-average shares outstanding, basic and diluted6,781,9766,757,7426,781,9766,629,949

* Non-GAAP net loss per share, basic and diluted may not total due to rounding.

View original source (GlobeNewswire)Instil Bio, Inc. on 6ix

Story so far

Earlier from Instil Bio

All Instil Bio news releases